CDK6 and breast cancer: In this study, we present a combination of two semi-analytical methods, HAM and MIM, to investigate the mathematical model of a BC treatment that combines an oral oestrogen receptor inhibitor called AZD9496 with palbociclib, a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.